The effect of Abl kinases,or Ponatinib challenging on breast cancer cells' global transcriptome

To gain insight into the signaling pathway(s) required for ABL1/ABL2-kinase activity or effected by Ponatinib treatment, we evaluated the consequences of single or double inactivation of ABL1/ABL2 cells, or Ponatinib treated cells on the transcriptome of breast cancer cells. To examine the consequences of depleting the ABL kinases, or Ponatinib treatment on the transcriptome of lung metastatic breast cancer cells we employed next generation sequencing (RNAseq) analysis. We found that 321 genes were significantly differently expressed in Ponatinib treated LM2 cells, and 73 genes were differently expressed in double inactivation of ABL1/ABL2 LM2 cells. However, only about 3.4 percent of Ponatinib affected genes can also be changed by ABL knocking down. Overall design: Samples were analyzed by pair of either control (DMSO) versus ABL Kinase inhibitor Ponatinib, Or using scrambled shRNA versus single or double inactivation of ABL1 and ABL2-specific shRNAs.